Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of fostamatinib in persistent/chronic immune thrombocytopenic purpura
2013-005454-30Phase 3Unknown
- Sponsor
- Rigel Pharmaceuticals, Inc.
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fostamatinib in immune thrombocytopenia (ITP), sponsored by Rigel Pharmaceuticals, Inc. Primary endpoints: Achievement and maintenance of a stable platelet count and Long-term safety of fostamatinib. Status: unknown.
02
Drugs
fostamatinib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2013-005454-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005454-30.